drugset

drugset / Trial / NCT00630396

Study of a Neuroprotective Drug to Limit the Extent of Damage From an Ischemic Stroke

NCT00630396 ↗

Phase 1/2 Completed 60 enrolled David Hess, MD National Institute of Neurological Disorders and Stroke (NINDS) · collab Oregon Health and Science University · collab University of Kentucky · collab

NaSingle-groupOpen-labelTreatment

Summary

The primary aim of this study is to find out which of 4 different doses of minocycline are safe and well tolerated so that we will know the optimal dose to test in future patients.

Timeline

Start: 2008-05
Primary completion: 2010-01
Completion: 2010-01

Publications

Results Fagan SC, Waller JL, Nichols FT, Edwards DJ, Pettigrew LC, Clark WM, Hall CE, Switzer JA, Ergul A, Hess DC. Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. Stroke. 2010 Oct;41(10):2283-7. doi: 10.1161/STROKEAHA.110.582601. Epub 2010 Aug 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Minocycline	Small molecule	1.5 mg/kg	Intravenous
Subject	Minocycline	Small molecule	2.25 mg/kg	Intravenous
Subject	Minocycline	Small molecule	3 mg/kg	Intravenous
Subject	Minocycline	Small molecule	5 mg/kg	Intravenous

Indications